When analyzing the induced pluripotent stem cell (iPSC) market, the technical aspects can often appear to be confusing. However, if you focus on a few key points of understanding, you’ll be able to understand key attributes that define the cell type, as well as their advantages and disadvantages. [Read more…]
Qkine Limited and Akron Bio Announce Strategic Partnership
Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics
Cambridge, UK and Boca Raton, FL – January 27, 2026 – Qkine Limited, a leading innovator in the development of high-quality growth factors and cytokines, and Akron Bio, a leading supplier of critical materials and services to the cell and gene therapy industry, today announced a strategic partnership focused on the joint development and global supply of ancillary materials to enable the development of stem cell-based therapeutics. [Read more…]
TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions
Monmouth Junction, NJ and Tokyo, Japan — January 7, 2026 — TheWell Bioscience Inc., a biotechnology company pioneering next-generation animal-free biofunctional hydrogels, and PeptiGrowth Inc., a leader in innovative synthetic peptide growth factors, today announced that the two companies have entered into a Marketing Collaboration Agreement to jointly promote cutting-edge solutions for stem cell culture, organoid development, and cell therapy manufacturing. [Read more…]
4 Major Areas of Commercialization for iPS Cells
Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type. In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.
In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”
A Complete Guide to Induced Pluripotent Stem Cell (iPSC) Core Facilities
Induced pluripotent stem cell (iPSC) core facilities are facilities created to facilitate the derivation and distribution of iPSC lines. These facilities promote iPSC research advances by providing disease-specific iPSC lines to researchers, thereby allowing more researchers to study mechanisms of disease and new therapeutic applications.
Induced pluripotent stem cell core facilities can also provide services related to iPSCs, including consultation and technical services, as well as training in iPSC technology.
Common services that the core facilities provide are derivation, maintenance, and characterization of iPSCs. They may also provide control iPSC lines, validated iPSC culture reagents, and more.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 24
- Next Page »